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Introduction 
Reports of reactivation of hepatitis B virus (HBV) and 
subsequent liver damage following the use of TNF 
antagonists have raised concerns regarding the 
safety of biologic agents in patients with a history of 
HBV infection [1]. A recent review of patients with 
psoriasis on biologic therapies including TNF 
antagonists, ustekinumab, and secukinumab 
determined that the risk of HBV reactivation is low in 
patients with isolated HBV core antibody positivity, 
whereas there is considerable risk in patients with 
chronic HBV infection. Although this review 
discussed ustekinumab, an IL-12 and IL-23 
antagonist, it did not provide an analysis of pure IL-
23 antagonists [2]. We report a patient with a history 
of HBV core antibody positivity and a history of 
palmoplantar psoriasis refractory to multiple 
biologic agents who was successfully treated with 
guselkumab, an IL-23 antagonist, without evidence 
of HBV reactivation or other liver complications. 
 
Case Synopsis 
A 46-year-old man was referred to our university-
based dermatology outpatient clinic for a six-year 
history of severe palmoplantar psoriasis, which had 
been refractory to methotrexate, acitretin, 
adalimumab, ustekinuamb, and secukinumab. His 
most recent therapy was eight months of 
ustekinumab, an IL-12 and IL-23 antagonist, which 
he tolerated without side effects but had incomplete 
clearance of his palmoplantar involvement. As a 
result, the decision was made to start him on 
guselkumab (100mg at 0 and 4 weeks, then every 8 
weeks). Baseline labs revealed a positive HBV core 
antibody, positive HBV surface antibody, negative 
HBV surface antigen, normal liver function tests (AST 
20, ALT 40), and a negative T-spot. We did not have 
access to his previous records and laboratory results, 
so it is unclear when he had an exposure to HBV. At 
one year of therapy, the patient had almost complete 
clearance of his psoriasis except for a small plaque on 
his right medial foot. Repeat labs revealed stable liver 
function tests (AST 19, ALT 40), persistently positive 
HBV core antibody, negative HBV surface antigen, 
negative HBV core IgM, and an HBV DNA level of 
zero. 
 
Case Discussion 
Guselkumab, an IL-23 antagonist, is a highly effective 
and well-tolerated therapy for patients with psoriasis 
[3]. Although there is some data on the safety of 
ustekinumab, an IL-12 and IL-23 antagonist, in the 
setting of HBV infection [2], there is little data 
Abstract 
Reactivation of hepatitis B virus (HBV) following the 
use of TNF antagonists has been reported and is a 
contraindication to use of these medications. 
Although the risk of reactivation of HBV during use of 
ustekinumab and secukinumab is low in patients 
with only HBV core antibody positivity, the risk is 
substantial in patients with chronic HBV infection. 
Less information is available regarding the use of 
pure IL-23 antagonists. Herein we discuss the 
successful treatment with guselkumab of a patient 
with HBV core antibody positivity, without evidence 
of HBV reactivation or other liver complications. 
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regarding the safety isolated IL-23 antagonists such 
as guselkumab in this population. 
 
Conclusion 
This case describes the successful treatment of a 
patient with treatment-refractory palmoplantar 
psoriasis with guselkumab, an IL-23 antagonist, in 
the setting of HBV core antibody positivity. Further 
studies are needed to confirm the safety of 
guselkumab in patients with HBV infection. 
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